BeOne Medicines Ltd. (ONC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, BeOne Medicines reported revenue of $5.34B, up 40.2% from $3.81B the year before. Net income was $286.9M (a 5.4% net margin), or $0.19 per diluted share. Gross margin was 87.5% and operating margin was 8.4%. Operating activities generated $1.13B of cash, leaving $941.7M of free cash flow. At fiscal year end, BeOne Medicines held $8.19B in total assets against $3.83B in total liabilities, including $4.55B of cash and equivalents.
Open the full interactive BeOne Medicines financials → Quarterly statements, key ratios, valuation history and price charts.
BeOne Medicines Key Stats
| Share Price | $349.08 |
|---|---|
| Market Cap | $40.42B |
| P/E Ratio | 141.3 |
| Revenue YoY Growth | +40.2% |
| 52-Week Range | $260.27 – $377.47 |
| Shares Outstanding | 1.45 billion (basic, 2026 Q2) |
BeOne Medicines Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $308.9M | $1.18B | $1.42B | $2.46B | $3.81B | $5.34B |
| Cost of Goods Sold | $70.7M | $164.9M | $286.5M | $3.29B | — | — |
| Gross Profit | $238.2M | $1.01B | $1.13B | $2.08B | $3.22B | $4.67B |
| Operating Income | -$1.66B | -$1.44B | -$1.79B | -$1.21B | -$568.2M | $447.1M |
| Pre-Tax Income | -$1.62B | -$1.44B | -$1.96B | -$825.8M | -$533.0M | $416.9M |
| Income Tax | -$17.7M | -$25.2M | $42.8M | $55.9M | $111.8M | $129.9M |
| Net Income | -$1.60B | -$1.41B | -$2.00B | -$881.7M | -$644.8M | $286.9M |
| Diluted EPS | -$1.47 | -$1.17 | -$1.49 | -$0.65 | -$0.47 | $0.19 |
BeOne Medicines Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.41B | $1.50B | $1.51B | $1.71B |
| Net Income | $124.8M | $66.5M | $227.4M | $237.0M |
| Diluted EPS | $0.08 | $0.05 | $0.15 | $0.16 |
BeOne Medicines Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.38B | $4.38B | $3.87B | $3.17B | $2.63B | $4.55B |
| Current Assets | $4.96B | $7.61B | $5.21B | $4.20B | $3.99B | $6.23B |
| Total Assets | $5.60B | $8.65B | $6.38B | $5.81B | $5.92B | $8.19B |
| Current Liabilities | $1.08B | $1.60B | $1.47B | $1.81B | $2.21B | $1.83B |
| Total Long-Term Debt | $3.38B | $4.01B | $3.71B | $6.29B | $7.43B | $1.02B |
| Total Liabilities | $1.73B | $2.40B | $2.00B | $2.27B | $2.59B | $3.83B |
| Shareholders' Equity | $3.87B | $6.24B | $4.38B | $3.54B | $3.33B | $4.36B |
BeOne Medicines Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.28B | -$1.30B | -$1.50B | -$1.16B | -$140.6M | $1.13B |
| Cash From Investing | -$3.17B | $640.7M | $1.08B | $60.0M | -$548.4M | -$276.2M |
| Cash From Financing | $5.20B | $3.64B | -$19.0M | $416.5M | $193.4M | $1.06B |
| Free Cash Flow | -$1.40B | -$1.56B | -$1.82B | -$1.72B | -$633.3M | $941.7M |
Figures from BeOne Medicines' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BeOne Medicines financials page for every line item.
BeOne Medicines Company Profile
| Ticker | ONC |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Pharmaceutical Preparations |
| Headquarters | Basel |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001651308 |
Frequently Asked Questions
What was BeOne Medicines' revenue in fiscal 2025?
BeOne Medicines (ONC) reported revenue of $5.34B for fiscal 2025.
What is BeOne Medicines' annual revenue history?
BeOne Medicines' annual revenue by fiscal year: 2020: $308.9M; 2021: $1.18B; 2022: $1.42B; 2023: $2.46B; 2024: $3.81B; 2025: $5.34B.
What was BeOne Medicines' net income in fiscal 2025?
BeOne Medicines reported net income of $286.9M for fiscal 2025.
What was BeOne Medicines' earnings per share (EPS) in fiscal 2025?
BeOne Medicines' diluted EPS was $0.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BeOne Medicines generate in fiscal 2025?
BeOne Medicines generated $941.7M of free cash flow in fiscal 2025.
What was BeOne Medicines' revenue last quarter?
In its most recent reported quarter (2026 Q2), BeOne Medicines reported revenue of $1.71B.
How much debt does BeOne Medicines have?
BeOne Medicines reported $1.02B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of BeOne Medicines are outstanding?
BeOne Medicines reported a weighted average of 1.45 billion basic shares outstanding in 2026 Q2.
What is BeOne Medicines' market cap?
Based on its latest closing price, BeOne Medicines (ONC) has a market capitalization of about $40.42B.
When does BeOne Medicines' fiscal year end?
BeOne Medicines' fiscal year end, as registered with the SEC, is December 31.
Where is BeOne Medicines headquartered?
BeOne Medicines lists its business address in Basel in its SEC filings.